Latest News and Press Releases

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected...

Optivate Is Here: A New Name, a Bolder Vision, and Continued Commitment to Elevating Ophthalmology

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and...

Continued clinical progress follows regulatory authorization to advance study First patient continues to show dramatic vision restoration GREENSBORO, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) --...

GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine company pioneering bio-printed tissues and organs with...

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Glaucoma - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a thorough analysis of over 100...

Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief...

All patients dosed with SPVN06 in Phase I/II trial continue to demonstrate a favorable safety profileInitial data readout for this novel gene-agnostic therapy expected in 2027 Paris, February 9,...

Dublin, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The "Ophthalmology Devices Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. In 2025, the ophthalmology...